Testing Blood Markers for Lung Disease in Rheumatoid Arthritis Patients
Tests blood markers KL-6 and calprotectin to detect lung disease in adults with rheumatoid arthritis.
Plain-language title generated from the registry record
Registry title: Novel Biomarkers in Assessment of Interstitial Lung Disease Associated With Rheumatoid Arthritis Patients
Key facts
- Where
- Asyut, EgyptSee the site
Where in Egypt
- Assiut University hospitalAsyut, EgyptNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Assiut University
- Trial code
- NCT07003451
- Record updated
- 28 August 2025
- Original description
- Assess Krebs von den Lungen-6 (KL-6) and Calprotectin as novel biomarkers for diagnosis of ILD among Rheumatoid arthritis patientsRead full original descriptionShow less
Novel Biomarkers in Assessment of Interstitial Lung Disease Associated With Rheumatoid Arthritis Patients
- Assess Krebs von den Lungen-6 (KL-6) and Calprotectin as novel biomarkers for diagnosis of ILD among Rheumatoid arthritis patients
Inclusion: Confirmed diagnosis of Rheumatoid arthritis, age > 18 years.
Exclusion: Patients with evidence of worsening or exacerbation of RA over the previous 6 months,; concomitant diagnosis of an active neoplasia, or; patients who had previously received radiotherapy,; End organ failure; Patients who refuse to participate in the study,.